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Background: Donepezil, an acetylcholinesterase inhibitor used in the treatment of Alzheimer’s disease, has been
widely cited in media and bioethics literature on cognitive enhancement (CE) as having the potential to improve
the cognitive ability of healthy individuals. In both literatures, this claim has been repeatedly supported by the
results of a small study published by Yesavage et al. in 2002 on non-demented pilots (30–70 years old). The
factors contributing to this specific interpretation of this study’s results are unclear.
Methods: We examined print media and interdisciplinary bioethics coverage of this small study, aiming to
provide insight into how evidence from research may be shaped within different discourses, potentially influencing
important policy, ethics, and clinical decisions. Systematic qualitative content analysis was used to examine how
this study was reported in 27 media and 22 bioethics articles. Articles were analyzed for content related to: (1)
headlines and titles; (2) colloquialisms; and, (3) accuracy of reporting of the characteristics and results of the study.
Results: In media and bioethics articles referencing this small study, strong claims were made about donepezil as a
CE drug. The majority of headlines, titles, and colloquialisms used enhancement language and the majority of these
suggest that donepezil could be used to enhance intellectual ability. Further, both literatures moved between
reporting the results of the primary study and magnifying the perceived connection between these results and the
CE debate that was alluded to in the primary study. Specific descriptions of the results overwhelmingly reported an
improvement in performance on a flight simulator, while more general statements claimed donepezil enhanced
cognitive performance. Further, a high level of reporting accuracy was found regarding study characteristics of the
original study, but variable levels of accuracy surrounded the presentation of complex characteristics (i.e., methods)
or contentious properties of the CE debate (i.e., initial health status of the study subjects).
Conclusions: Hyped claims of CE effects cannot be completely accounted for by sheer inaccuracy in reporting. A
complex interaction between the primary and secondary literature, and expectations and social pressures related
to CE appears to drive enthusiastic reports.Background
The phenomenon of cognitive enhancement (CE)—the idea
that one might improve upon their typical, or “healthy,”
level of cognitive performance through the use of pharma-
ceuticals originally developed to treat medical conditions—
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reproduction in any medium, provided the ordebate. Within both literatures, arguments have been made
in favour of providing these so-called “CE drugs”a to profes-
sionals, such as surgeons and pilots, and school children
[3-6]. Such arguments contribute to the perception that CE
drugs are both efficacious and in demand, which has fuelled
calls for the development of regulatory frameworks to
control their use [7]. Already, medical professional soci-
eties such as the American Academy of Neurology [8,9]
and governmental ethics committees [10] have deliberated
over the proper policy response to the use of pharmaceuti-
cals for enhancement purposesb. Yet, an informed public,
medical, and ethical response to CE remains limited by atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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practice. Indeed, studies examining the body of evidence
informing this debate have found it to be inconsistent
[11], inadequate and insufficient [12], and study outcomes
to be incompatible and limited in number [13], making
any generalizable conclusions elusive.
Why CE has generated a high level of public and pro-
fessional attention despite a limited body of evidence is a
provocative question. Previous research has shown that
the media may play a role in disseminating information,
driving interest and fuelling misrepresentation of the
level of evidence [14-16]. However, it is increasingly
acknowledged that the media does not act in isolation
[17]. Overstatements of therapeutic effect in media arti-
cles have been found to be “faithfully reported” [18]
from the conclusions of scientific articles. The media
may be overly deferential to claims made with the au-
thority of science, which can be problematic as the
claims referenced may involve speculation [19]. Further,
a “spatial dynamic,” [20] may exist whereby expectations
of positive outcomes are generated from little evidence
due to the interaction of multiple stakeholders, including
research communities, funding agencies, and patient
groups as well as the media. Such a multimodal inter-
action may account for the interest in one pharmaceutical,
methylphenidate, as a CE drug. Specifically, speculation
over the ability of methylphenidate to change lives may
have introduced “a cycle of expectation” [13]. This expect-
ation—like the speculation it arises from—has loose con-
nections with empirical evidence, making it resistant to
detailed discussions of the limitations of current efficacy
data that should curtail interest [13].
Donepezil as a case example to explore the generation
and persistence of academic and media claims of CE
effects despite limited evidence
The study of donepezil provides a possible window into
how CE more broadly became and remains a topic of
focused interest for the public and academia alike, despite
a limited body of supporting evidence. The evolution of
donepezil, an acetylcholinesterase inhibitor, from a treat-
ment for Alzheimer’s disease (AD) to a contender in the
CE debate is intriguing. First, the medical value of donepe-
zil in AD has been contested. It took funding agencies,
such as the UK’s NICE, decades to gather sufficient
evidence of effect to support their endorsement of the
drug as a treatment for mild and moderate dementia [21].
Further, in this medical context donepezil has been
described as a “cognitive enhancer” because it slows down
AD-related cognitive decline. However, this use of the
term CE does not refer to the phenomenon of CE that we
are discussing in this paper (see note b, above), creating
an opportunity for misinterpretation of the drug’s effects
and applications if studies on CE in a clinical populationare confounded with studies of CE which specify a
“healthy” population. Indeed, out of 446 studies on the ef-
fect of acetylcholinesterase inhibitors reviewed by Repantis
et al., only 20 had results relevant to the cognitive enhance-
ment of already healthy individuals [12].
Second, media and bioethics articles that claim done-
pezil has a CE effect rely heavily on the results of a
single study, which in addition to being a very small
study (n = 18) with limited results, is open to different
interpretations in the way described above: references
to CE may refer to the phenomenon of enhancing
healthy individuals, or could connote the type of CE
referred to in the AD literature. The study, published in
2002 in Neurology, reported an effect of donepezil on
the ability of non-demented pilots to retain complex
skills in a flight simulator [22]. Specifically, the study
(which we will abbreviate as the “Donepezil flight simu-
lator study” or DFSSc in this paper, see Table 1) found
that “[d]onepezil appears to have beneficial effects on
retention of training on complex aviation tasks in non-
demented older adults” [22]. The American Academy
of Neurology, like many others, cited this study as
supporting evidence for the existence of CE. However,
the use of the results of this study as evidence that
donepezil is a cognitive enhancer is problematic for
several reasons. First, the authors of the DFSS have
clarified that the applicability of their data is limited,
stating: “[o]ur results should not be interpreted as a rec-
ommendation for the use of donepezil as a drug to im-
prove flight performance” [23]. Specifically, their results
are based on a simulated flight experience, not the piloting
of an airplane.
Second, in the introduction section of the DFSS, the
authors justify their use of donepezil as the intervention
drug based on previous work that has led to the “‘cholin-
ergic hypothesis’ which proposes that part of age-related
cognitive decline is caused by reduced cerebral choliner-
gic function” [22]. One of the goals of the study was to
test whether donepezil could improve flight performance
in older pilots as the United States prevents pilots over
60 from flying due to concerns about the effects of aging
[22] on flying ability. Thus, one of the premises of this
study was the idea that donepezil may improve the per-
formance of pilots whose cognitive and psychomotor
skills may have been affected by aging. Though the idea
that pilots’ ability is affected by aging is a controversial
claim, the authors of the DFSS justified donepezil as the
appropriate intervention on these grounds. Thus, it ap-
pears the study set out to determine whether donepezil
could improve performance in the flight simulator by
treating the reduction in cholinergic function. Inter-
preted in this way, the study may be considered as an
investigation of a treatment for age-related cognitive
decline (which would connote a disease state), rather
Table 1 Brief overview of the Donepezil flight simulator study (DFSS)
Background and methods In 2002, Yesavage et al. conducted a study on 18 pilots, aged 30–70 with a mean age of 52, who were split into
placebo and control groups. The groups were randomized, and after seven 75 minute long practice tests
on a flight simulator (where the baseline for the study was also calculated), the drug group was administered 5 mg
of donepezil per day for 30 days. On day 30 both groups performed two more flight simulator tests. The primary
outcome measure of the study was the change in flight score from the flights performed on day 30, when compared
with those on day zero. Four different flight components were assessed during the flight simulations: communication,
traffic avoidance, emergencies, and approach to landing.
Results and conclusions The results of the study state: “flight performance of the pilots in the donepezil group changed little from performance
after the initial training to 30-day post-treatment… whereas it declined in pilots in the placebo group” (see Table 3
for a more detailed description of the results).
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ralizability of the study’s results to the CE debate.
Third, subsequent detailed reviews of studies on the
effects of acetylcholinesterase inhibitors on healthy pop-
ulations, which included the DFSS, have since concluded
that none of the studies provide sufficient evidence to
support the CE claims made about donepezil [12,24].
Finally, in contrast to the non-medical use of stimulants
for CE [25,26], no strong prevalence data exists that
bolsters claims of a CE effect by providing evidence of
a perceived CE effect by users. However, donepezil,
supported by reference to the DFSS, persists as a key
reference in the CE debate, contributing to the perception
that CE is possible, and, as already seen, shaping discus-
sions about clinical practice.
Evidently there is tension between, on the one hand,
academic and media discourse about donepezil as a CE
drug and, on the other, the level of evidence supporting
this claim. This study aimed to examine how media
coverage and bioethics discussion of the DFSS has
shaped donepezil as a CE agent, evaluating what
factors might account for the presentation of an interpret-
ation of the DFSS in popular and scholarly articles
that is not promoted by the study’s authors. Addition-
ally, we sought to explore the ethical issues at stake—
specifically, the impact of hyped claims about the CE
on autonomous decision-making and the physician-
patient relationship—as CE continues to be propagated as
a possibility.
Methods
This study analyzes the reporting of one study, the DFSS,
in public and academic literature. We conducted a sys-
tematic review of international (i.e., including Canada, US,
UK) print media (M) and interdisciplinary bioethics litera-
ture (BE) where references to the DFSS appeared within a
discussion of CE.
Sampling
To develop our media sample we searched the Factiva
database using key word searches to find English
language media articles on CE published between 2002
and 2009, inclusively, based on existing media samplingmethods [15,27]. The start date was selected to capture
media articles released following the publication of the
DFSS. Key word searches were used to broadly identify
articles that addressed cognitive enhancement, donepe-
zil, and the DFSS. The terms “donepezil”, “Aricept”,
“E2020”, “acetylcholinesterase”, “enhance”, “Yesavage”,
“Mumenthaler”, “Neurology”, “pilots”, “flight simulator”,
“memory”, “illicit drugs”, “study aid,” and their variants
(e.g., singular and plural forms) were used in different
search combinations to maximize relevant results. Initial
searches yielded 339 potential articles. To develop our
bioethics sample we performed citation searches in the
academic databases Pubmed, Google Scholar, Medline,
and Proquest. A total of 154 articles (7, 85, 21, 41, respect-
ively) were identified that specifically referenced the DFSS.
Articles were excluded from our samples if they were
duplicates, referenced a different study by the same
authors, focused on the medical use of donepezil (e.g.,
Alzheimer’s, schizophrenia, bipolar, mild cognitive im-
pairment, impaired attention, dementia), or referred to
the study in the wider context of animal research. For
the bioethics sample, non-peer reviewed and non-
English language publications, as well as articles pub-
lished after 2009 were also excluded. Inclusion criteria
were then applied, restricting our samples to only include
articles that discussed CE. The media sample was further
examined to ensure that each article either made direct
reference to the DFSS or made indirect reference to the
study by presenting at least four study characteristics (e.g.,
year, journal, author, author affiliation, subjects, methods,
results, limitations, ethical issues raised) that clearly
established its identity. Our final sample included 27
international print media articles and 22 interdisciplinary
bioethics papers.
Content and discourse analysis
A coding guide was developed for the systematic analysis
of articles. It was inductively generated and informed by
previous qualitative content analysis of media coverage
of CE performed by two of the authors (CF and ER; [2]).
Extensive pretesting on a sub-set of articles was con-
ducted to tailor this previous coding guide to the specific
research objectives of this project. The coding strategy
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lysis of content captured information related to three
distinct categories within each article: (1) headlines and
titles; (2) colloquialisms used to refer to donepezil; and,
(3) reporting of the characteristics and results of the
DFSS. One author (LW) was responsible for conducting
the initial coding. One co-author (CF or ER) reviewed
the coding and the other (ER or CF) resolved any dis-
agreements over challenging codes. Complex coding was
conducted using the QSR NVivo 8 software (Doncaster,
Australia) while simpler components of coding were car-
ried out in Excel spreadsheets.
Analysis of headlines and titles
Headlines and titles were separated from the body of the
articles and coded based on 1) whether they claimed an
enhancing property; 2) what property, if any, was high-
lighted; and, 3) how the context of CE was portrayed
(i.e., if they suggest that CE is currently happening, is
anticipated, is questionable, or is undesired).
Analysis of colloquialisms
Colloquialisms, such as “smart pill” [28], which were used
to explicitly refer to donepezil, were coded separately. To
ensure connection with the DFSS, colloquialisms were
coded only if they were found within the paragraph where
the DFSS was referenced; or, in bioethics articles, if there
was a direct structural connection to the reference (i.e.,
the colloquialism was found in the heading of the section
where the study was referenced). Colloquialisms were
coded with respect to the enhancement property they
imply (e.g., CE in general or memory specifically).
Analysis of result claims, qualifying clauses, and study
characteristics
Media and bioethics articles were systematically coded
to capture how they conveyed results, qualifying clauses
and study characteristics. Only information that was
clearly linked to the reference of the DFSS found in each
bioethics and media article was retained for coding. The
specific coding guide applied to the reporting of the
DFSS included the identification of: (1) the characteris-
tics of the study (e.g., sample size, subject information,
tests used, dosage information); (2) statements of the
results or findings of the study broken into two levels:
“specific” results (i.e., an explicit statement of the results
of the study) and “extended” results (i.e., when the au-
thor of the article interpreted or restated the “specific”
results to introduce the study, or to connect it to wider
issues); and, (3) qualifying clauses related to the rigor or
limitations of the study. The original study was also
coded using the coding guide used for both media and
bioethics articles. Descriptive statistics were used to
quantify and qualify the distribution of headlines, titles,colloquialisms, and claims made about the results of the
DFSS within the different codes, as well as qualifying
clauses.
Specific analysis of study characteristics by Euler’s circles
Logical analysis by Euler’s circles was applied to reports
of the characteristics of the DFSS found in media and
bioethics articles to examine how accurately they reflect
those of the study itself. Euler’s circles provide a clearly
visible and easily replicated method for the logical analysis
of how closely a claim relates to or represents another,
primary, claim [29]. Logical analysis was conducted by
division of secondary claims into five distinct logical clas-
ses, called proposition classes, each representing a differ-
ent relationship between the primary and secondary
claims (see Figure 1 for proposition classes) [29,30].
Media and bioethics reports of study characteristics
were identified as B (claims; B) and actual study cha-
racteristics as A’. Claims made by media and bioethics
articles were then placed in the proposition class that
best reflected their relationship to the A’ characteristic.
The distribution of claims between proposition classes
and categories of study characteristics was then cal-
culated on a one article per category basis (even if that
article made two distinct claims), yielding a basic unit of
analysis we refer to as an “article-claim” (see the legend
of Figure 1 for further detail).
Results
Headlines and titles
To assess the main themes conveyed to readers of arti-
cles that cite the DFSS, we analyzed the media headlines
and bioethics titles (see Additional file 1 and Additional
file 2 for complete lists of articles). The most common
topic portrayed by media headlines was a general claim
of an enhancement effect (N = 17/27; 63%), which was
almost always related to the use of a pharmaceutical
(N = 16/17; 94%). The majority of these headlines related
the enhancement effect to intellect or cognition (N = 9/17;
53%; e.g., Brain-boosting drugs could soon become the
smart choice [31]) or stated that an enhancement effect
was currently possible (N = 13/17; 76%) or anticipated
(N = 2/17; 12%). A minority of headlines presented wary
or skeptical comments regarding the possibility of en-
hancement (N = 6/17; 35%; e.g., Can taking a pill make
you brainy? [32]), and no headlines implied that CE is
undesirable. Within the headlines that did not focus on
intellect or cognition, enhancement effects on general
mind/brain (N = 3/17; 18%), memory (N = 3/17; 18%), at-
tention (N = 2/17; 12%), youth (N = 1/17; 1%), or perform-
ance (N = 1/17; 1%) were conveyed.
Of the nine headlines that did not present an enhance-
ment effect, the majority claimed that there had been
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Figure 1 Accuracy of study characteristics reported. The first column gives values for “A’”, the claims made in the study, while the following
five columns provide the number of articles that made “B”, alternative claims that describe the same study characteristic, in each of five Euler
classes (representing varying degrees of accuracy). Absolute numbers represent how many different articles had at least one B description in each
sub-category. Each article was counted only once per sub-category (e.g., non-demented, placebo controlled) of study characteristic even if it
made two or more separate claims that fell into that sub-category. This metric is captured by the term “article-claim”. Thus, the numbers in each
cell refers to the number of “article-claims” made per sub-category added together for each category in each class. To calculate the total number
of article-claims made per class, the numbers of article-claims per category were added together. Theoretically, a single article could account
for 15 category claims since they could have made a claim about each sub-category of study characteristics. To calculate the total number of
article-claims made per category, the numbers of article-claims per class were added together. Here, a single article could account for a maximum
of 5 times the number of sub-category claims that is possible in each category, since they could have made a claim about each sub-category that
fell into each class.
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of these headlines specified that the breakthrough was
pharmacological (N = 4/7; 57%).
Most titles of the bioethics articles (N = 16/22; 73%),
featured the term “enhancement;” the majority specific-
ally referring to “neurocognitive enhancement” (N = 11/
16; 69%). Bioethics titles generally suggested a more philo-
sophical or critical approach to the issue of CE than media
headlines did, but they still implied that CE was a possibil-
ity as they introduced the potential for concern, (N = 10/
16; 63%; e.g., Neurocognitive enhancement: what can we
do and what should we do? [34]). In contrast to the media
headlines, only 19% (N = 3/16) of bioethics titles related
enhancement to pharmaceutical use.Additional themes in the bioethics titles were: 1) the
role of medicine with respect to CE (N = 8/22; 36%);
mainly, the implications of the sliding treatment-enhance-
ment scale, though two articles focused on the possibility
of cognitive enhancement for physicians; and, 2) the pro-
gress or evolution of CE and appropriate responses for the
future (N = 6/22; 27%). None of the titles in our sample
implied medical use of pharmaceuticals.
Colloquialisms
To determine whether explicit connections were made
between donepezil and CE, we examined the colloquial-
isms that were used to refer to donepezil. Colloquialisms
were used in 52% of media articles (N = 14/27) and 45%
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to refer to donepezil, with a total of 20 distinct colloquial-
isms used in media and 12 in bioethics articles. The
majority of colloquialisms used enhancement language
(N = 10/20 M, 50%; N = 11/12 BE, 92%). A large propor-
tion of both media and bioethics colloquialisms that used
enhancement language specifically referred to cognitive or
brain enhancement (N = 4/10 M, 40%; N = 8/12 BE, 73%,
e.g., “brain-enhancing drugs” [35,36]). Additionally, many
colloquialisms referenced an effect on intelligence though
they did not use explicit enhancement language. When
these intelligence colloquialisms were combined with
those that referred explicitly to cognitive enhance-
ment, 50% of media and 75% bioethics colloquialisms
conveyed an effect on intelligence (N = 10/20 M, N =
9/12 BE).
Enhancement colloquialisms also specified an effect on
memory (N = 5/10 M, 50%; N = 1/12 BE, 1%) e.g., “mem-
ory enhancing pills” [28]), youth (N = 1/10 M,), safety (N =
1/10 M) and performance (N = 1/10 M). Two bioethics ar-
ticles claimed the general effect of enhancement, withoutTable 2 Colloquialisms* used in media and bioethics discours
Media




“Smarts” “so-called ‘smart drugs’” [46]
“so-called smart pills” [31]
“smart pill” [28]
“the ‘older’ smart drugs” [33]
“the existing smart drugs” [33]
“cognition drugs” [47]
Memory enhancement “memory-enhancing drugs” [48]
“memory-enhancing pills” [28]
“Alzheimer drug boost for healthy
“memory-enhancing medications”
Others “performance-enhancing drugs” [4
“the safety-enhancing drug” [37]
“these ‘fountain of youth’ drugs” [4
“new brain boosters” [51]
“brain cosmetics” [52]
“a memory pill” [53]
*Terms are divided based on the type of effect implied (e.g., brain enhancement, m
**Or group of drugs containing donepezil.specifying what characteristic or properties are en-
hanced (e.g., “enhancements” [54]). Only one media
article used a colloquialism that could refer to a
medical treatment, rather than enhancement (e.g., “a
memory pill” [53]).
Reporting of the results of the DFSS
To determine how the results of the DFSS were reported
in media and bioethics discourses, we summarized
the claims made in the primary study (Table 3), as well as
those found in media [28,31-33,35,36,46-53,55-66] and
bioethics articles [6,8,24,38-45,54,67-75] (Additional file 3
and Additional file 4).
The DFSS
In its abstract, the DFSS claimed that donepezil had
“beneficial effects on retention” as pilots who took done-
pezil “showed greater ability to retain the capacity to
perform” (Table 3). In the results section, a significant
difference was described between the drug and control
groups related to “in flight performance change.” Herees that explicitly refer to the drug donepezil**
Bioethics
7] “cognitive enhancement drugs” [38]





“‘magic potions’ to enhance our ‘wisdom’” [45]
“smart drugs” [45]
“memory enhancing agents” [45]
memory” [49]
[50]




Table 3 Statements of the results of the DFSS as they appeared in the original paper
Findings of the DFSS
Abstract
“After 30 days of treatment, the donepezil group showed greater ability to retain the capacity to perform a set of complex
simulator tasks than the placebo group, p 0.05.”
“Donepezil appears to have beneficial effects on retention of training on complex aviation tasks in nondemented older adults.”
Results
“After 30 days of treatment, there was a significant difference between the donepezil group (n = 9, mean age 51.2 years) and
the placebo group (n = 9, mean age 53.1 years) in flight performance change (F 6.1, p 0.05, effect size 0.58)”
“Overall, flight performance of the pilots in the donepezil group changed little from performance after initial training to 30-day
post-treatment (0.06 z-score units; SD 0.31), whereas it declined in pilots in the placebo group (0.24 z-score units; SD 0.19)”
“To help focus the discussion of the likely locus of drug effects, post hoc analyses of flight component difference scores were
computed. These scores reflect differences in performance between treatments over the course of treatment. Examination of the
figure suggests the largest effects of donepezil were on the emergency scanning (effect size 0.56) and the approach to landing
scores (effect size 0.52)”
Discussion
“Given the extensive literature on the effects of acetylcholinesterase inhibitors on memory, we were not surprised to find some
effects of the drug on ability to retain a practiced skill in pilots”
“Nonetheless, these results are consistent with previous studies in nondemented adults that have reported that cholinesterase
inhibitors improve cognitive performance.”
“The association of cholinergic drugs with better attention has lead investigators to suggest that part of the benefit of cholinergic
drugs on memory performance may be mediated through attentional components involved in working memory. This suggestion
is supported by the current data that show the strongest drug effects on emergency tasks and the approach to landing. The
emergency tasks involve visually scanning the instrument panel for aberrant readings. The approach to landing requires sustained
divided attention to maintain proper altitude, speed, and heading”
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pilots in the donepezil group changed little, whereas it
declined in pilots in the placebo group” (Table 3). In the
discussion the authors stated that their results were
consistent with those of previous studies that “reported
that cholinesterase inhibitors improve cognitive perfor-
mance” (Table 3). They also extrapolated a connection
between cholinesterase inhibitors, working memory and
memory performance (Table 3).
Media and bioethics articles
All media and bioethics reports of the results of the DFSS,
save one bioethics article, enthusiastically portrayed a bene-
ficial effect of donepezil. This lone bioethics critique oc-
curred at the level of extended results where the article
expressed concern that: “the available evidence does not ap-
pear to support the widely cited conclusion that donepezil
improves the retention of training” [24].
Specific results
Reporting of specific results was high (N = 23/27 M,
85%; N = 18/22 BE, 82%; Additional file 3 and Additional
file 4), yielding a total of 36 M and 19 BE specific results
claims. Improvement language was used in 94% of
media claims (N = 34/36 M) and 84% of bioethics claims
(N = 16/19B). Of those claims that used improvement
language, improved task performance by the pilots who
took donepezil was mentioned in 71% of media and 63%
of bioethics claims (N = 24/34 M; N = 10/16 BE), mainly
referring to their performance in the flight simulator
and emergencies; memory performance was mentionedin 29% of media claims and 25% of bioethics claims
(N = 10/34 M; N = 4/16 BE); and brain performance was
mentioned in only 6% of bioethics claims (N = 1/16 BE).
Explicit enhancement language (i.e., the term enhance-
ment or a variation on that term) was used in 3% of
media claims and 11% of bioethics claims (N = 1/36;
N = 2/19). The media claim that used enhancement lan-
guage referenced brain performance, while both bioethics
claims referenced task performance.Extended results
The majority of articles also reported extended results
(N = 16/27 M, 59%; N = 13/22 BE, 59%; Additional file 3
and Additional file 4), yielding a total of 23 M and 14 BE
extended results claims. Improvement language was
used in 65% of media claims (N = 15/23 M) and 36% of
bioethics claims (N = 5/14 BE). Of those claims that used
improvement language, improved task performance by
the pilots who took donepezil was mentioned in 33% of
media and 20% of bioethics claims (N = 5/15 M; N = 1/5
BE); memory performance in 33% of media claims and
40% of bioethics claims (N = 5/15 M; N = 2/5 BE); and
brain performance in 33% of media claims and 40% of
bioethics claims (N = 5/15 M; 2/5 BE).
Explicit enhancement language was used in 30% of
media claims and 50% of bioethics claims (N = 7/23 M;
N = 7/14 BE). Enhanced memory was referenced in 57%
of media claims and 43% of bioethics claims (N = 4/7 M;
N = 3/7 BE); brain performance was referenced in 43%
of media claims and 57% of bioethics claims (N = 3/7 M;
N = 4/7 BE).
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We also examined the qualifying clauses made in the
DFSS and reported by a handful of media and one bio-
ethics article (N = 4/27 M, 15%; N = 1/22 BE, 5%). The
authors of the original study presented both practical and
epistemic qualifications. Practical qualifications warned of
potential side-effects of the drug (in the CE context)
and a need for a larger sample size or further tests.
These qualifications were each only reported by two
media articles (7%). The epistemic qualification that
“these results should not be interpreted to advocate
widespread use of donepezil in nondemented popula-
tions” [22]) was reflected in three media articles (11%).
The second epistemic qualification that “[a]lthough these
findings may support interpretations of the effects of
cholinergic augmentation on cognitive processing, the
precise neurochemical mechanisms of action remain to
be fully delineated” [22] was only reported by one bio-
ethics article (5%).
Reporting of the study characteristics of the DFSS
To establish whether the characteristics of the DFSS
(e.g., subject information, sample size (n), study de-
sign) were accurately reported in media and bioethics
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those found in the DFSS (“same” class; Figure 1).
However, when the categories of study characteristics
were analyzed independently, we found two categories
that did not reflect this trend: the “subjects” category
and the “methods” category. The “subjects” category was
also the category that had the largest total number of
article-claims (Figure 1). In addition to finding a high
number of article-claims about the “subjects” category in
the “same” class, we found a high number in class “IO,”
the “Some A’ are B, some A’ are not B” class. In this
class, part of the claim might be accurate, or under cer-
tain circumstances it may be accurate, but not always.
We also found a high number of article-claims in the
specifications (“All B are A’”) class (Figure 1). Figure 2
demonstrates the range of qualitative differences pos-
sible in the translation of discrete categories of informa-
tion with respect to information about study subjects.
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claims can represent the same characteristic category
but fall into different proposition classes.
Discussion
This study examined media and bioethics coverage of
the DFSS, which serves as supporting evidence in the
CE debate. We specifically focused on how the DFSS is
reported in media and bioethics articles that engage in
the debate in order to characterize how secondary lite-
rature has contributed to the claim that donepezil has
CE effects.
Our key findings demonstrate that both media and
bioethics articles use the DFSS as support to make
strong claims about the use of donepezil for CE pur-
poses, specifically for increasing intelligence and mem-
ory. These claims are most pronounced in the headlines
and titles of articles that engage in the CE debate, as well
as in the colloquialisms that are used to explicitly refer
to donepezil within the context of a discussion about CE
(Table 2). Emphasis is placed on the possibility that
donepezil could affect cognition or intellectual capacity
while consistent use of enhancement language implies
that this effect is both above one’s “healthy” level of cog-
nition and is a desirable or laudable goal. This supports
the previous findings of a study that found that media
and bioethics discourses were generally enthusiastic in
portraying CE effects of methylphenidate on cognition
[2]. However, we did see a difference between headline
and title references to pharmaceutical use as well as to
the potential medical use of donepezil (i.e., for memory
restoration). While media headlines reference both
topics, bioethics titles focus on enhancement and reflect
coverage of general issues related to the CE debate. This
could indicate that donepezil is rarely examined in the
bioethics literature as a cognitive enhancer in its own
right (i.e., for memory), but has become part of the
larger debate on CE where it is taken to be an illustrative
example. Alternatively, it could point to the media inter-
preting the primary study in different ways, i.e., as both
a treatment study and an enhancement study, while
bioethics articles unilaterally interpreted the study as
evidence of an enhancement effect.
Our analysis of how the results of the DFSS are depicted
in media and bioethics articles is consistent with the pres-
entation of strong claims for CE that we found in head-
lines, titles, and colloquialisms. Amplification of a CE
effect occurs both within and across individual arti-
cles as the findings of the DFSS are consistently pre-
sented at two levels (i.e., specific or extended; Additional
file 3 and Additional file 4). In both literatures, the drug
effect is reported with reference to three broad categories
of characteristics, namely, task performance, memory, and
brain, mind, or mental capacity. The way this effect isconveyed, either through improvement language (which
could connote a treatment or an enhancement effect)
or through explicit enhancement language, and what cat-
egory of characteristic is emphasized, changes depending
on the level at which the result is reported.
We found a clear trend to use explicit CE language
and to report effects on memory and brain, mind, and
mental capacity when articles report the findings as
extended results. This trend is particularly salient in
bioethics articles, where the majority of result claims use
enhancement language at this level. The proportion of
claims about DFSS results made by the media that use
enhancement language does increase at the extended
level; however, the majority of media claims use improve-
ment language. When improvement language is used at
this level, both literatures equally make reference to all
three categories of performance improvement.
Conversely, when reporting results at the specific level,
both literatures use a higher proportion of improvement
rather than explicit enhancement language. Both lite-
ratures overwhelmingly report an improvement in task
performance, followed by an improvement in memory.
An improvement in brain function is only raised as a
specific result of the study by bioethics articles. Specific
reports of improvements in performance (and memory
to a lesser degree) are often associated with discrete
tasks, such as flying a flight simulator or performing an
emergency procedure. However, further specification of
what aspects of these broad characteristics are influ-
enced by donepezil is rare (i.e., executive function, short
or long-term memory) as is a precise description of the
original level of significance of the findings or what
trend contributed to this significant difference (i.e., a
decrease in the performance of the pilots in the placebo
group). Too few articles use enhancement language at
this level to establish any trend.
Evidently, the findings of the DFSS that are reported,
as well as the level of detail conveyed, change substan-
tially as they are reported at the specific and extended
levels. The direction of this change—from claims of
memory and task improvement to claims of enhanced
cognitive traits—as articles move away from a focused
discussion of the DFSS to report generalized findings
suggests that the results of this study may have been
hyped as they were used to support the CE debate.
However, this data also reflects the duality of study inter-
pretations we found in the headlines, titles, and colloqui-
alisms and may be attributable to the study being
interpreted in different ways (i.e., as both a treatment and
enhancement study).
Our final investigation of how accurately media and
bioethics articles translate and present the characteristics
of the DFSS (e.g., subjects, study design) showed that
overall most study characteristics are accurately identified;
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found high levels of variability in claims related to
the “subjects” and “methods” categories. The information
provided on the ‘subjects’ category is straightforward in
the DFSS, so these discrepancies stand out. There is a
trend to report subject characteristics using the language
of the CE debate, e.g., “healthy,” or in relation to the
expectation that the drug may be useful for “fighter” or
“commercial” pilots (Figure 2). Close examination of the
DFSS itself shows that information on the methods used
may be difficult for a lay audience to interpret, making
accurate restatement of these characteristics legitimately
difficult. This variable accuracy in the reporting of study
characteristics, combined with our findings related to the
reporting of the study’s results, suggests that the strong
claims of CE effects associated with donepezil use cannot
be accounted for by simple inaccuracy in reporting of the
primary paper. More complex interactions seem to be
governing the accurate dissemination and interpretation
of the findings of the study.
We explore the potential factors involved in the hyped
portrayal of the results of the DFSS and the potential
ethical implications for society and clinical decision-
making in the following discussion points: 1) the magni-
fication of the connection between the results of the
DFSS and the CE debate; and, 2) the ethical challenges
of hyped claims of CE effects for clinicians.
The magnification of the connection between the results
of the DFSS and the CE debate
Further comparison of the results of the DFSS that were
reported in media and bioethics articles with the conclu-
sions drawn by the authors of the study in its “discussion”
section provides insight into how difficult aspects of the
CE debate may have contributed to how the results of the
DFSS came to be reported as support for CE.
The findings presented by the DFSS in its “abstract” or
“results” section (Table 3) do not claim an enhancement
in performance, rather they claim that: “the donepezil
group showed greater ability to retain the capacity to
perform” [22] (Table 3, abstract). The majority of specific
results reported by both media and bioethics articles
may be said to have accurately conveyed this result as they
claimed improvement in task performance or memory
(Additional file 3 and Additional file 4).
In the discussion of the DFSS the authors move
from discussing the specific effect they found to generalize
an improvement in cognitive performance. They pre-
sent the qualifying clause: “these results should not
be interpreted to advocate widespread use of donepe-
zil in nondemented populations” [22] before stating
that “[n]onetheless” [22], their results are consistent with
those of previous studies, which “have reported that
cholinesterase inhibitors improve cognitive performance”[22]. As discussed above in the background section, the
interpretation of these results as evidence that donepezil
improves flight performance has since been discredited
by the authors. A recent review also concluded that the
DFSS only demonstrates that donepezil “might im-
prove the retention of training on complex aviation
tasks” [12] (emphasis added). Finally an additional study
that reviewed the level of evidence provided by the DFSS
and other studies on acetylcholinesterase inhibitors simi-
larly concluded: “the available evidence does not appear to
support the widely cited conclusion that donepezil im-
proves the retention of training” [24]. Thus, while provid-
ing an acceptable lay interpretation of the data, it can be
concluded that specific result claims magnify the results
of the DFSS.
Beyond generalizing memory to cognition, the authors
go on to dedicate the final paragraph of their discussion
to raising concerns about CE, directly raising and naming
the concept of CE for the first time. Careful examination
of this section exposes how difficult aspects of the CE
debate, namely understanding the distinction between
references to CE that connote a medical term in the AD
literature and those that connote CE in healthy individuals
and assessing whether a study on an aging population can
be considered to be a CE study, may have compounded
the challenge of accurately interpreting the study, such
that articles’ interpretations are understandably biased
towards a CE effect.
Throughout the paragraph, the authors consider what
would happen if CE becomes a possibility for intellec-
tually intact individuals and discuss ethical issues tightly
linked to the CE debate, such as access, justice, fairness,
and regulation. Yet, at the same time, they imply that
their study population was not healthy: they discuss the
potential demand for CE from aging individuals without
AD who seek to remedy their “deficits” [22]. In this way,
the authors make a clear connection between the find-
ings of their study and a CE effect, yet it remains unclear
whether they intended to distinguish CE as found in the
AD literature from CE discussed in the ethics debate.
Thus, the extended result claims of CE effects that were
reported in media and bioethics articles seem to be
attributable, at least in part, to different messages found
in the original publication as the authors attempted to
connect their findings to those of other studies and,
potentially, to the CE debate.
Problems created in the dissemination of research
results emerging from discrepancies within one primary
study are certainly not unique to the CE debate or the
study we examined. For example, a study on the dissemin-
ation of attention deficit hyperactivity disorder (ADHD)
research (primary studies that associate polymorphisms
of a specific gene with ADHD) found: (1) internal incon-
sistencies between claims made in the results and those
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claim in the summary, while data that limit this conclu-
sion were only present in the results section; and (3) the
inappropriate extrapolation of findings to therapeutic
prospects [18]. These data offer support for our find-
ing of a shift in emphasis between the data reported
in the results section of the DFSS and the generalized
conclusion offered in the study’s discussion that this
result may lend support to the CE debate. Previous
research on developments in biotechnology, including
neurotechnology, has also shown that the majority of
authors include both a qualifying clause in their paper
that addresses the uncertainty inherent in their data,
as well as a main explanation of their data, that is
designed to provoke discussion with their peers. Yet,
often only the main or simplified explanation is
widely disseminated in print media [20,76] and ob-
served by stakeholders exposed to media coverage of
cognitive enhancement [77]. Further, explanations that
were reported in the media have been found to be
inconsistent with what was actually reported in the
study, reflecting “different versions of future rele-
vance” [20] as the data is interpreted and translated.
This phenomenon provides greater insight into our
finding that media and bioethics articles reported
more generalized conclusions than qualifying clauses
and helps to account for the further discrepancy ob-
served in the facts reported by media and bioethics
articles.
Finally, the presence of expectations in a field of
research has also been found to influence the claims made
by authors of both primary and secondary literature [20].
Brown [20] describes how anticipation of a prospective
future is crucial for project development, funding, and
creativity. Yet, hype around expectations can threaten the
legitimacy of a research project. Unfortunately, the per-
petuation of expectations rarely occurs without hype and
strong claims of an effect. Where there are expectations, a
spatial dynamic is often created “whereby the further we
travel from the source of knowledge production, the more
colourful and flamboyant become the promissory pro-
perties of knowledge” [20]. This trend is consistent with
previous work on the reporting of neuroscience research
[15,27]. Our current data may well indicate the presence
of such a spatial dynamic. In some germinal form, we saw
that the primary authors’ description of their findings
moved from memory retention in the results section to
CE in the discussion. This trend was magnified in claims
made in media and bioethics articles given their presenta-
tion of the results of the DFSS on two levels (specific and
extended). Finally, when we consider the strong claims
and latent expectations for CE found in our colloquialism
and headline data, there is additional support for the
hypothesis that there is a distinct trend to elaborateon findings, based on expectations rather than reflecting
uncertainty, as claims are further removed from the
source of the data.
The ethical challenges of hyped claims of CE effects for
clinicians
One ethical implication of print media and bioethics
literature hyping claims of CE effects while referencing
primary research arises from the effect of hype on pre-
existing expectations about CE drugs. Specifically, it has
been widely recognized that one of the risks of en-
dorsing the use of pharmaceuticals for enhancement
purposes is that it may perpetuate social pressures, such
as the pressure to perform, be productive, highly intelli-
gent, or competitive [78]. Unchecked, social pressure
may perpetuate social values that are not in line with the
interests of the population as a whole, or do not reflect
the interests of all individuals [79]. These performance-
oriented values, though viewed by some as integral to a
thriving society (e.g. [80]), may negatively impact indi-
viduals’ ideas of their own self-worth, fostering anxiety
and discontent regarding genuinely lived experiences
[78], and subsequently inducing a society that instead
celebrates those traits that are the most in line with
quantifiable economic and military principles of prod-
uctivity. The long-term social consequences of drug use
for CE purposes are unknown; however, the risk of
inducing a “medicated normality”, has been raised,
where a loss of cultural and social diversity, accom-
panied by intolerance towards difference, would mani-
fest as an assault on the autonomy of individuals
[10]. Others have raised the possibility that such drug
use could induce unanticipated changes to the com-
plex biosocial and psychological functions of the brain,
altering our social behaviour in an altogether different
way [81].
Research on the role of social pressure in the context
of CE has isolated a “funnel phenomenon,” [82] where
social pressure covertly drives individual choice in the
use of methylphenidate for CE among students [82].
When prompted, stakeholders in the debate (e.g., stu-
dents, health care providers) firmly believed that students’
personal values guided their decision to use methylphen-
idate for CE (i.e., students acted autonomously). However,
they also believed that social pressure to perform was so
strong in the academic community that it created “a form
of social determinism leading to conformity with so-
cial values through a concession of personal values”
[82]. The authors concluded that personal values are an
ornamental, rather than substantial, factor in decision-
making. This finding has substantial implications in the
context of our own results. If health care profes-
sionals believe individuals are making autonomous
choices, yet external pressures are implicitly shaping
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individual is being coerced to change a trait becomes
challenging and worthy of attention from an ethics
standpoint.
It has been recognized that as requests for “neuroen-
hancements” enter the clinical realm, physicians will be
left with the difficult task of interpreting strong claims,
modifying expectations, and addressing social pressure.
However, recently published guidelines on how neuro-
logists should deal with these requests [8] concluded
that neurologists were sufficiently aware of these social
factors and thus left out specific recommendations on
how to take social pressures into account, opting instead
to support a physician-patient discussion [8]. As demon-
strated by the previous data, there is a risk that within
the context of the patient-physician relationship it will
be difficult to determine whether the individual is in fact
making informed decisions based on appropriate claims.
Further, in its absence from the guidelines, the presumed
importance of this issue may be overlooked. An exten-
ded patient-physician discussion may uncover reasons
for the request; however, without specific guidelines to
address misguided expectations and related social pres-
sure in the clinical context, physicians may consider
further attention to these issues unnecessary or even
consider the presence of social pressure as an ethically
justifiable reason to prescribe.
It has been suggested that the description of the lack
of data on the safety and efficacy of cognitive enhancers
would deter physicians from prescribing them [8]. How-
ever, as our study shows, this dearth of scientific evidence
can be difficult to grapple with due to hyping of the results
in media and bioethics literature. Indeed, these very
guidelines cited the DFSS as evidence in support of
the efficacy of these drugs [8]. Clearly, there is an import-
ant interaction between strong public claims about CE,
pre-existing social pressure, the existence of expectations
for CE, and the ability to adequately disseminate in-
formation on safety and efficacy. Mitigating misguided
claims, social pressure, and expectations will be an
ongoing process. Organizations have begun developing
explicit recommendations on how to deal with social
pressures surrounding CE agents [10]; however, more
work is needed to help physicians integrate knowledge of
social factors and circumstances that shape decision-
making [83]. As the CE debate continues, caution should
be further applied to avoid complicity with negative social
norms that surround intellectual disability. Attention to
disability ethics literature may help bioethicists and clini-
cians become acquainted with the obligations we have to
support people with disabilities.
Another area to explore is how information could be
provided to the public based not on single studies, but
on more comprehensive and authoritative reviews of theliterature. Primary researchers should consider means to
reduce misappropriation of their work, and journalists
and editors should be accountable for writing headlines
that draw in readers while conserving accuracy.
Limitations
In spite of broad searches and the use of multiple data-
bases, our sample may not be exhaustive of all articles
on non-medical use of donepezil with reference to the
DFSS. The small sample size, which may well reflect the
scope of the CE debate, makes it difficult to make any
wide-reaching conclusions. Like other qualitative con-
tent and discourses analyses, though coding was double-
checked and thoroughly pilot tested, controlling for
subjectivity of data gathering and analysis is challenging
and represents another study limitation. Further, our
findings should not be interpreted as an accusation of
the authors of the DFSS or of the specific journalists or
scholars who were authors of the media and bioethics
articles in our sample. We understand that the reported
media statements reflect an amalgamation of data and
opinions and do not necessarily reflect the opinions of
the authors. Accordingly, the content of our sample
should be viewed as a reflection of what members of the
public have access to, rather than the individual voice of
the author per se, and our findings should be considered
a detailed exploration of the challenges of interpreting
complex data and their contribution to contemporary
ethics debates about neurological advances in healthcare
and beyond.
Conclusion
Our findings regarding which factors contribute to the
presence of strong media and bioethics claims that
donepezil has a CE effect support the general finding
that both media and academic literature often magnify
the limited conclusions that can be drawn from basic
research, putting them in line with expectations that
may be heavily influenced by prominent social pressures.
A complex interaction between the authors of primary
and secondary literature, generated in part by the tenu-
ous distinction between treatment and enhancement
that sets the premise for the CE debate, and in part by
the presence of widespread expectations and social pres-
sures, may contribute to this phenomenon. Caution is
needed to both explicitly account for social pressure and
acknowledge the limited data on safety and efficacy as
we continue to discuss the use of drugs for CE, particu-
larly in the clinical context.
Endnotes
aWe consider the term “CE drug” as well as the prac-
tice descriptor “CE” to be problematic. They imply that
increasing cognition is both possible and beneficial. We
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script. However, to enhance readability and be consistent
with the current literature, we use these terms to refer-
ence those drugs and related practices that have been
discussed as being capable of increasing cognition.
bThough we recognize the transient definition of med-
ical need, for the purpose of this article we employ
Daniels’ definition “[c]haracterising medical need…implies
a contrast between medical services that treat disease
(or disability) conditions and uses that merely enhance
human performance” [17] as it reflects what is commonly
held to be the distinction between drug use for medical
need and that for enhancement purposes.
cFor the purpose of this paper we will refer to this
study as the Donepezil Flight Simulator Study (DFSS; we
encourage readers unfamiliar with this study to consult
Table 1 for further details).
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